HHS seeks contractors for HITECH Act implentation

The Department of Health and Human Services (HHS) recently announced four notices seeking contractors to assist and evaluate the administration of grant programs from the Office of the National Coordinator (ONC) that promote state health information exhange and the creation of health IT training centers.

HHS is looking for contractors who will:
  • Assess the overall progress towards the goals of the Health IT for Economic and Clinical Health (HITECH) Act of 2009. Separate program evaluations will be conducted that focus on the effectiveness of the State Health Information Exchange Cooperative Agreement Program, the Regional Extension Center Program, the Beacon Communities Program and the IT Professionals in Healthcare.
  • Identify performance measures and develop and conduct a formative and summative evaluation of the State Health Information Exchange Cooperative Agreements Program required under HITECH. This will focus primarily on the effectiveness of the state cooperative agreements in establishing information exchange capability by studying the progress of states in implementing and expanding information exchange.
  • Provide technical assistance to State Health Information Exchange Cooperative Agreement awardees in governance, finance, technical infrastructure, operations and accountability.
  • Establish a customer relation management (CRM) software-as-a-service (SaaS) solution for regional health IT extension centers.

The announcements can be viewed at the Federal Business Opportunities Web site.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.